medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2021, Number 3

<< Back Next >>

Rev Nefrol Dial Traspl 2021; 41 (3)

Antibody production against COVID-19 in hemodialysis patients

Yesil GS, Eren D, Saatci E, Deniz EM, Ihsan GA

Language: English
References: 14
Page: 159-165
PDF size: 291.55 Kb.


ABSTRACT

Introduction: Dialysis patients may have a very high prevalence and death rate for COVID-19. The aim of this study is to show the level of antibody against SARS-CoV-2 in hemodialysis and staff working in the same dialysis center. Methods: Anti-SARS-CoV-2 IgG antibodies were studied in 156 hemodialysis patients and 27 staff. After a 5-minute resting period, blood pressure was measured and then subsequent to an approximately 12- hour fasting period, blood sample were drawn for biochemistry parameters and anti-SARS-CoV-2 IgG antibodies. Results: Three of hemodialysis patients were diagnosed with COVID-19 in March and their PCR tests were positive. The symptoms of these patients were extreme fatigue and muscle weakness. Anti-SARSCoV- 2 IgG antibodies tests were performed on all patients and staff in July. In total, 13/156 (8.3%) patients were diagnosed as COVID-19 based on anti-SARSCoV- 2 antibodies. The other 10 patients were asymptomatic. The staff and 143 hemodialysis patients had IgG (-). Hemodialysis patients who had anti-SARS-CoV-2 IgG (+) antibodies had decreased level of haemoglobin and high levels of C-reactive protein and alkaline phosphatase. Conclusions: Antibody tests are particularly important for detecting people with COVID-19 who have few or no symptoms. It has also been seen that the spread of infection in the dialysis center can be prevented by very strict precautions.


REFERENCES

  1. Kliger AS, Silberzweig J. Mitigating risk of COVID-19in dialysis facilities. Clin J Am Soc Nephrol. 2020;15(5):707-9. doi: 10.2215/CJN.03340320.

  2. Rombolà G, Brunini F. COVID-19 and dialysis: whywe should be worried. J Nephrol. 2020;33(3):401-3.doi: 10.1007/s40620-020-00737-w.

  3. Ma Y, Diao B, Lv X, et al. COVID-19 inhemodialysis (HD) patients: report from one HDcenter in Wuhan, China. medRxiv; 2020. doi:10.1101/2020.02.24.20027201.

  4. Fu D, Yang B, Xu J, Mao Z, Zhou C, Xue C. COVID-19infection in a patient with end-stage kidney disease.Nephron. 2020;144(5):245-7. doi: 10.1159/000507261.

  5. Ikizler TA. COVID-19 and dialysis units: what do weknow now and what should we do? Am J Kidney Dis.2020;76(1):1-3. doi: 10.1053/j.ajkd.2020.03.008.

  6. Stock da Cunha T, Gomá-Garcés E, Avello A, Pereira-García M, Mas-Fontao S, Ortiz A, González-ParraE. The spectrum of clinical and serological featuresof COVID-19 in urban hemodialysis patients. J ClinMed. 2020;9(7):2264. doi: 10.3390/jcm9072264.

  7. Betjes MG. Immune cell dysfunction and inflammationin end-stage renal disease. Nat Rev Nephrol.2013;9(5):255-65. doi: 10.1038/nrneph.2013.44.

  8. Vaziri ND, Pahl MV, Crum A, Norris K. Effectof uremia on structure and function of immunesystem. J Ren Nutr. 2012;22(1):149-56. doi: 10.1053/j.jrn.2011.10.020.

  9. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, ChenYK, et al. Antibody responses to SARS-CoV-2 inpatients with COVID-19. Nat Med. 2020;26(6):845-8. doi: 10.1038/s41591-020-0897-1.

  10. Goicoechea M, Sánchez Cámara LA, Macías N,Muñoz de Morales A, Rojas ÁG, Bascuñana A,et al. COVID-19: clinical course and outcomesof 36 hemodialysis patients in Spain. Kidney Int.2020;98(1):27-34. doi: 10.1016/j.kint.2020.04.031.

  11. Alberici F, Delbarba E, Manenti C, Econimo L,Valerio F, Pola A, et al. A report from the Brescia RenalCOVID Task Force on the clinical characteristics andshort-term outcome of hemodialysis patients withSARS-CoV-2 infection. Kidney Int. 2020;98(1):20-6.doi: 10.1016/j.kint.2020.04.030.

  12. Zhou H, Xiao X, Wang X, Tan X, Zhang X, He T, etal. Clinical features of hemodialysis patients confirmedwith Coronavirus Disease 2019 (COVID-19): aretrospective case-control study. medRxiv; 2020. doi:10.1101/2020.07.06.20147827.

  13. Anders HJ, Bruchfeld A, Fernández Juárez GM, FloegeJ, Goumenos D, Turkmen K, et al. Recommendationsfor the management of patients with immunemediatedkidney disease during the severe acuterespiratory syndrome coronavirus 2 pandemic. NephrolDial Transplant. 2020;35(6):920-5. doi: 10.1093/ndt/gfaa112.

  14. Li J, Xu G. Lessons from the experience inWuhan to reduce risk of COVID-19 infection inpatients undergoing long-term hemodialysis. ClinJ Am Soc Nephrol. 2020;15(5):717-9. doi: 10.2215/CJN.03420320.




2020     |     www.medigraphic.com